Rebecca Robbins

Many employers and government programs won’t cover costly obesity medications. A lawsuit is challenging one such policy.

Experts say the exploitation of a loophole in the patent system has contributed to high prices for inhalers.

The company is heavily reliant on a cancer drug that could be targeted by a program intended to lower drug prices.

With a history as a date rape drug, a medication needed strict distribution controls. Its maker, Jazz Pharmaceuticals, used that to delay competition.

AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. The monopoly is about to end.